Chemed Corporation (CHE) Stock: Price, Forecast & Analyst Target
Chemed Corporation (CHE) — MoonshotScore 85/100 (Exceptional band), calculated Nov 18, 2026. Price $551.33 (+0.84%), as of the Nov 19, 2026 trading session; market cap $7.15B. Expected results Feb 24, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 147.64× (market value Nov 16, 2026; cash Sep 30, 2026) · expected results Feb 24, 2027
Chemed Corporation · CHE · NYSE · Healthcare · Medical - Care Facilities
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered): Chemed Corporation operates an unusual combination of completely unrelated businesses under the same corporate roof: a major national hospice care provider and a widespread plumbing and drain cleaning service. Investors weighing the stock must evaluate whether the steady cash flows from the plumbing division will continue to reliably support the specialized, highly regulated operations of the end-of-life medical care segment.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Chemed (CHE)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality and a strong balance sheet, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Sound; Valuation: Full; Growth Durability: Flat; Momentum: Surging.
- EPS beat 4 of the last 8 reports
- Altman Z 9.84 · Piotroski F 7
- ROE 32.1% · ROA 16.4% · current ratio 1.11 · earnings yield 3.9% · free-cash-flow yield 4.1%
Helping: business quality, balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 84 | Exceptional | |
| 84 | Exceptional | |
| 84 | Exceptional | |
| 84 | Exceptional | |
| 85 | Exceptional | |
| 85 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $551.33 | |
| Change on the day | +0.84% | |
| 52-week range | $365.21–$562.24 | |
| Market capitalisation | $7.15B | |
| Price / earnings (trailing) | 26.10 | |
| Shares traded on the day | 236.1K | |
| Beta (volatility vs the S&P 500) | 0.5 | |
| Dividends per share (last 12 months) | $2.60 | |
| Dividend yield (last 12 months) | 0.48% |
Why Chemed scores 85
Share price, last 12 months +22.9%
$446.01 $548.20
What the price assumes
9.7% a year of free-cash-flow growth for ten years is what a $7.15B market value () asks for.
The price already assumes faster growth than the last 5 years delivered. Anything short of an acceleration leaves room to disappoint. It also runs ahead of the analysts' revenue path.
Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $295.45M. Inputs: FMP statements, estimates and quote.
How the stock reacts to earnings
EPS beat in 5 of the last 12 reports (2024–2026); the stock still fell the next session after 1 of those beats. Average first-session move: 7.6% either way.
- +5.1%Feb ’24
- -7.0%Apr ’24
- -0.1%Jul ’24
- -12.0%Oct ’24
- +6.4%Feb ’25
- -5.6%Apr ’25
- -10.6%Jul ’25
- +6.6%Oct ’25
- -15.3%Feb ’26
- +12.9%Apr ’26
- +5.9%Jul ’26
- +4.0%Oct ’26
Every report, with revenue and five-session moves
| Report | EPS | Revenue | Next session | 5 sessions |
|---|---|---|---|---|
| Beat | In line | +4.0% | +4.0% | |
| Beat | Beat | +5.9% | +6.0% | |
| Beat | Beat | +12.9% | +13.9% | |
| Miss | Miss | -15.3% | -12.2% | |
| Miss | Miss | +6.6% | +0.5% | |
| Miss | Miss | -10.6% | -8.2% | |
| Beat | In line | -5.6% | +0.3% | |
| In line | In line | +6.4% | +8.1% | |
| Miss | Miss | -12.0% | -12.4% | |
| Miss | In line | -0.1% | +5.3% | |
| Miss | In line | -7.0% | -8.2% | |
| Beat | In line | +5.1% | +6.4% |
Misses cost real money here: the average first-session move after a miss was -6.4%.
What management is saying differently
Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.
- New this call: “roto rooter”, “ebitda margin”, “adjusted ebitda”, “excluding medicare” — none of them came up in Q2 FY2026.
- Gone quiet: “water restoration”, “combined program”, “drain cleaning”, “florida combined” — regular themes last call, absent this time.
- Tone: Cautious words such as “may”, “could” and “headwind” rose from 1.7 to 3.4 per 1,000 words, and confident words such as “record” and “strong” fell from 2.4 to 2.
Management chose more careful words than a quarter earlier. Tone shifts like this often show up in the numbers a quarter or two later.
Our track record on this stock
Since the score went from 83 to 85 while the share price moved +1.8% through .
The score has stayed in the Exceptional band across the stretch we have recorded; we grade each band change three months after it happens.
The crowd against our signals
- Analysts: 50% of 10 rate it a buy; the average target sits +15.2% from the price of $551.33.
- Last 90 days: 1 upgrade and 0 downgrades among 4 rating actions.
- Our signals: Exceptional band; strongest pillar Business Quality (90), weakest Growth Durability (48).
Our signals are more constructive than the crowd, led by Business Quality.
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
Finally, based on the company's financial results through 09/30/2026, we expect to finish the year at or slightly above the high end of our full year 2026 adjusted EPS guidance discussed in our second quarter 26 earnings press release dated July 28, 2026.
Michael D. Witzeman · Statement from
How to read these dates
Events are in date order; the spacing is not a duration scale. A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for Chemed (CHE): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Chemed (CHE), and what does it report?
Short answer · as of
The company generates revenue from palliative care through its medical segment, deploying physicians, nurses, and clergy to support patients.
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
Alongside the healthcare operation, it runs a vast network of corporate branches, contractors, and franchisees offering plumbing, excavation, and water restoration services to residential and commercial clients.
Reported financial results merge these disparate operations into a consolidated income statement. While the medical classification dictates how the stock is categorized by data providers, the plumbing segment drives a significant portion of the total revenue, meaning the top line relies heavily on home repair demand as much as it does on hospice admissions.
What do the latest results show for Chemed (CHE)?
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
Recent financial results show steady revenue growth paired with operating profits that routinely exceed analyst estimates for earnings per share. The business consistently generates positive operating cash flow, which easily covers capital expenditures, pointing to a highly cash-generative model across the medical and plumbing segments.
Management frames their forward-looking statements as routine, noting that they recently adjusted their guidance primarily to maintain their historical pattern of updating expectations midway through the calendar cycle. This suggests the underlying operations are performing predictably without forcing emergency revisions.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $690.94M Sep 30, 2026
- Latest quarter · SG&A
- $111.47M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- $96.42M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $690.94M | Not available | $111.47M | $96.42M |
| Jun 30, 2026 | $673.25M | Not available | $115.20M | $89.20M |
| Mar 31, 2026 | $657.51M | Not available | $114.32M | $84.58M |
| Dec 31, 2025 | $639.34M | Not available | $105.50M | $100.65M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $690.94M Oct 27, 2026
- Latest report · revenue estimate
- $685.04M Oct 27, 2026
- Latest report · revenue vs estimate
- Above estimate Oct 27, 2026
- Latest report · EPS vs estimate
- Above estimate Oct 27, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 27, 2026 | $690.94M | $685.04M | $6.7500 | $6.4400 |
| Jul 28, 2026 | $673.25M | $665.04M | $6.0600 | $5.6000 |
| Apr 23, 2026 | $657.51M | $649.82M | $5.6500 | $5.3000 |
| Feb 25, 2026 | $639.34M | $659.09M | $6.4200 | $7.0200 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2026 | $691M | $72M | $5.45 (diluted) |
| Jun 2026 | $673M | $68M | $5.13 (diluted) |
| Mar 2026 | $658M | $66M | $4.85 (diluted) |
| Dec 2025 | $639M | $77M | $5.48 (diluted) |
What are the financial strengths and risks for Chemed (CHE)?
Short answer · as of
Cash and short-term investments were $48.43M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $56.59M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
The balance sheet carries more total debt than liquid cash and short-term investments, resulting in a net debt position. However, the operations print robust free cash flow, and the company distributes a portion of this cash back to shareholders through regular, recurring dividend payments.
The primary risk comes from the regulatory environment surrounding the hospice segment, where changes to government reimbursement rates or compliance costs would squeeze margins. Concurrently, a severe housing market downturn could stall the plumbing and restoration side, exposing the company to simultaneous pressures across completely different macroeconomic drivers.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $56.59M Sep 30, 2026
- Previous quarter · operating cash flow
- $84.81M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $56.59M | −$18.72M |
| Jun 30, 2026 | $84.81M | −$15.52M |
| Mar 31, 2026 | $88.22M | −$17.12M |
| Dec 31, 2025 | $133.53M | −$16.35M |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Chemed (CHE)?
Short answer · as of
The next earnings report is expected on Feb 24, 2027. The number it tests is the $25.78 EPS analysts carry for it.
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
When the company reports its next financial results, analysts will watch whether the medical segment can maintain its profit margins against persistent labor cost pressures in the healthcare sector. Observers will also look for signs that the plumbing division is sustaining its project volume, as any weakness there would dilute the overall earnings momentum.
Following the recent midyear guidance update, attention shifts to how closely actual results track management expectations. Any deviation from the projected path would test the reliability of their forecasting cadence and potentially alter the current trajectory of shareholder returns.
What management is planning
How does Chemed compare with its peers?
Short answer
Chemed's score ranks tied for 4th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
Most healthcare facilities are focused entirely on patient care, hospital management, or clinical services. Chemed stands apart by explicitly pairing a highly regulated, labor-intensive medical business with a commercial and residential plumbing service, creating an operational structure rarely seen in public markets.
This structure means the company does not trade on the pure demographic trends typical of a dedicated senior care facility. Instead, its valuation reflects a blend of healthcare stability and the cyclical, weather-dependent nature of emergency home repairs, making direct comparisons to traditional medical providers fundamentally flawed.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.77 Nov 18, 2026 | $5.24B | 92 5-pillar Nov 18, 2026 | |
| $186.07 Nov 18, 2026 | $10.7B | 91 5-pillar Nov 18, 2026 | |
| $64.02 Nov 19, 2026 | $12.7B | 87 5-pillar Nov 18, 2026 | |
| Chemed (CHE) — this page | $551.33 | $7.15B | 85 |
| $31.61 Nov 19, 2026 | $4.74B | 85 5-pillar Nov 18, 2026 | |
| $132.25 Nov 19, 2026 | $13.0B | 81 5-pillar Nov 18, 2026 | |
| $20.13 Nov 19, 2026 | $10.5B | 80 5-pillar Nov 18, 2026 | |
| $140.34 Nov 19, 2026 | $8.90B | 77 5-pillar Nov 18, 2026 | |
| $156.24 Nov 19, 2026 | $9.83B | 76 5-pillar Nov 18, 2026 | |
| $176.59 Nov 19, 2026 | $10.3B | 74 5-pillar Nov 18, 2026 | |
| $84.80 Nov 19, 2026 | $9.37B | 73 5-pillar Nov 18, 2026 | |
| $85.80 Nov 19, 2026 | $14.6B | 66 5-pillar Nov 18, 2026 | |
| $16.26 Nov 19, 2026 | $4.57B | 38 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $620.00 – $650.00
- Consensus target
- $635.00
- Median target
- $635.00
- Revenue estimate
- $2.73B
- EPS estimate
- $25.78
Consensus record · Captured .
Measured against a quoted price of $551.33 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 13, 2026
- Transactions
- 33
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 11
- Other transactions
- 22
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 99.3% Period end Sep 30, 2026
- Reporting holders
- 550 Period end Sep 30, 2026
- Previous quarter · holders
- 537 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 1,452,540 |
| Aqr Capital Management LLC | 859,657 |
| Vanguard Portfolio Management LLC | 855,538 |
| Vanguard Capital Management LLC | 586,586 |
| Acadian Asset Management LLC | 461,748 |
Tracked investors
Which of the 16 named investors we follow held CHE in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.05% | $10.70M | Added +3.9% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Chemed (CHE)?
Common Questions About CHE (Healthcare)
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered); the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
Which operating division generates the majority of the total revenue?
The medical care operations bring in a larger share of the overall top line compared to the plumbing and drain cleaning side. Even so, the home service division remains a crucial pillar of the business, contributing heavily to the combined financial results.
Why is the business categorized as a healthcare stock when it operates a plumbing service?
Standard industry classifications group stocks based on the largest source of their revenue. Since the palliative care division outearns the home repair segment, the corporate entity sits among medical care facilities. Investors buying the stock for healthcare exposure are also acquiring a major residential and commercial plumbing operation.
How does the non-medical segment manage its nationwide service network?
The plumbing and restoration division reaches customers through a layered structure that includes company-owned branches alongside independent contractors and franchised locations. This model allows the business to perform excavation, water restoration, and drain cleaning for residential and commercial clients across various regions.
What specific types of clinical care does the medical division offer?
Rather than operating traditional hospitals or general practice clinics, the healthcare segment focuses entirely on end-of-life and palliative care. The network deploys physicians, nurses, home health aides, and spiritual clergy to provide direct comfort and emotional counseling to terminally ill patients and their families.
What is the CHE stock price today?
The last price recorded for Chemed Corporation (CHE), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the CHE price target?
The analyst consensus price target for Chemed Corporation (CHE), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Does CHE pay a dividend?
Yes. The dividend yield of Chemed Corporation (CHE) over the last 12 months, with its date, is listed under Price & valuation on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 80 figures on this page — 2 from SEC filings and earnings calls, 67 from Financial Modeling Prep (FMP), 5 with no recorded source, 5 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-13), by section of the research
ETFs that hold CHE
Funds in our ETF coverage that list CHE among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| VictoryShares THB Mid Cap ETF (MDCP) | 4.00% |
